NCT04327232

Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 184 (estimated)
• Sponsor: National University Hospital, Singapore · Academic / Other
• Sex: All
• Age: 21 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This proposal details the implementation of an international (Singapore and New Zealand) multi-centre study to test a novel therapeutic strategy aimed at reducing the burden of atrial fibrillation - an important medical condition with major healthcare implications. Unique aspects of this study include i) a non-arrhythmic treatment target (mineralocorticoid receptor antagonism) -targeting the arrhythmogenic substrate of AF before it becomes permanently established, ii) the use of pacemaker monitoring capability to accurately document AF burden, thus increasing the power of the study and iii) multi-national collaborative, double blind design.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Spironolactone 25mg	Mineralocorticoid Receptor Antagonists
DRUG	Placebo oral tablet	Placebo

Timeline

• Start date: 2018-05-23
• Primary completion: 2022-05-31
• Completion: 2022-05-31
• First posted: 2020-03-31
• Last updated: 2020-03-31

Locations

4 sites across 1 country: Singapore